Ana Bercovici
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Receptor Mechanisms and Signaling, Neuropeptides and Animal Physiology, Phosphodiesterase function and regulation, Cholinesterase and Neurodegenerative Diseases, Pharmacological Receptor Mechanisms and Effects
Most-Cited Works
- → Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity(1997)80 cited
- → The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia(2011)33 cited
- → The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia(2012)26 cited
- → The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety(2009)25 cited
- → The anxiolytic-like profile of the nociceptin receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octane-3-carboxamide (SCH 655842): Comparison of efficacy and side effects across rodent species(2011)23 cited
- → Synthesis and structure–activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2(2007)17 cited
- → Bioavailable pyrrolo-benzo-1,4-diazines as Nav1.7 sodium channel blockers for the treatment of pain(2014)15 cited
- → Synthesis and structure–activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1(2007)13 cited
- → Synthesis and evaluation of potent and selective c-GMP phosphodiesterase inhibitors(1999)13 cited
- → Discovery of pyrrolo-benzo-1,4-diazines as potent Nav1.7 sodium channel blockers(2014)13 cited